BMS-986104 is under clinical development by Bristol-Myers Squibb and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BMS-986104’s likelihood of approval (LoA) and phase transition for Rheumatoid Arthritis took place on 14 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BMS-986104 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BMS-986104 is under development for the treatment of atopic dermatitis and rheumatoid arthritis. The drug candidate is administered orally. It acts by targeting sphingosine 1-phosphate (S1P1) receptor. It was also under development inflammatory bowel disease and multiple sclerosis.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
Quick View BMS-986104 LOA Data
|Highest Development Stage|